[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR102568469B1 - Cxcr3 수용체 조정제로서의 (r)-2-메틸-피페라진 유도체 - Google Patents

Cxcr3 수용체 조정제로서의 (r)-2-메틸-피페라진 유도체 Download PDF

Info

Publication number
KR102568469B1
KR102568469B1 KR1020177022437A KR20177022437A KR102568469B1 KR 102568469 B1 KR102568469 B1 KR 102568469B1 KR 1020177022437 A KR1020177022437 A KR 1020177022437A KR 20177022437 A KR20177022437 A KR 20177022437A KR 102568469 B1 KR102568469 B1 KR 102568469B1
Authority
KR
South Korea
Prior art keywords
methyl
trifluoromethyl
triazol
thiazol
pyrimidin
Prior art date
Application number
KR1020177022437A
Other languages
English (en)
Korean (ko)
Other versions
KR20170102355A (ko
Inventor
에파 카로프
엠마누엘 마이어
Original Assignee
이도르시아 파마슈티컬스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이도르시아 파마슈티컬스 리미티드 filed Critical 이도르시아 파마슈티컬스 리미티드
Publication of KR20170102355A publication Critical patent/KR20170102355A/ko
Application granted granted Critical
Publication of KR102568469B1 publication Critical patent/KR102568469B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
KR1020177022437A 2015-01-15 2016-01-14 Cxcr3 수용체 조정제로서의 (r)-2-메틸-피페라진 유도체 KR102568469B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2015/050691 2015-01-15
EP2015050691 2015-01-15
PCT/EP2016/050659 WO2016113346A1 (en) 2015-01-15 2016-01-14 (r)-2-methyl-piperazine derivatives as cxcr3 receptor modulators

Publications (2)

Publication Number Publication Date
KR20170102355A KR20170102355A (ko) 2017-09-08
KR102568469B1 true KR102568469B1 (ko) 2023-08-18

Family

ID=55129889

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177022437A KR102568469B1 (ko) 2015-01-15 2016-01-14 Cxcr3 수용체 조정제로서의 (r)-2-메틸-피페라진 유도체

Country Status (16)

Country Link
US (1) US10047080B2 (es)
EP (1) EP3256469B1 (es)
JP (1) JP6595003B2 (es)
KR (1) KR102568469B1 (es)
CN (1) CN107207491B (es)
AR (1) AR103399A1 (es)
AU (1) AU2016207990B2 (es)
BR (1) BR112017015116A2 (es)
CA (1) CA2972954C (es)
ES (1) ES2712727T3 (es)
MX (1) MX2017009292A (es)
PL (1) PL3256469T3 (es)
RU (1) RU2706232C2 (es)
TR (1) TR201901977T4 (es)
TW (1) TWI698434B (es)
WO (1) WO2016113346A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10259807B2 (en) * 2013-07-22 2019-04-16 Idorsia Pharmaceuticals Ltd. 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
EP3245203B1 (en) * 2015-01-15 2018-11-14 Idorsia Pharmaceuticals Ltd Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
WO2018011265A1 (en) * 2016-07-13 2018-01-18 Idorsia Pharmaceuticals Ltd Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
CN110183388A (zh) * 2019-06-06 2019-08-30 常州合全药业有限公司 一种2-（1h-1,2,4-三氮唑-1-乙基）醋酸的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015011099A1 (en) 2013-07-22 2015-01-29 Actelion Pharmaceuticals Ltd 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004523529A (ja) 2001-01-23 2004-08-05 イーライ・リリー・アンド・カンパニー メラノコルチンレセプターアゴニスト
WO2002059107A1 (en) 2001-01-23 2002-08-01 Eli Lilly And Company Substituted piperidines/piperazines as melanocortin receptor agonists
WO2002070511A1 (en) 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
KR101255356B1 (ko) 2002-06-12 2013-04-17 케모센트릭스, 인크. 염증 및 면역 질병의 치료를 위한 ｃｃｒ１ 길항물질로서사용하기 위한 1-아릴-4-치환된 피페라진 유도체
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
GB0315203D0 (en) 2003-06-28 2003-08-06 Celltech R&D Ltd Chemical compounds
WO2005035534A1 (ja) 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
WO2005042516A2 (en) 2003-10-22 2005-05-12 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
AU2004293026B2 (en) 2003-11-21 2012-01-19 Array Biopharma Inc. AKT protein kinase inhibitors
US20060276465A1 (en) 2003-12-26 2006-12-07 Eisai R&D Management Co., Ltd. 1,2-di(cyclic) substituted benzene compounds
MY140489A (en) 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
HUE033089T2 (en) 2004-10-22 2017-11-28 Janssen Pharmaceutica Nv C-FMS kinase inhibitors
US7645755B2 (en) 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
MX2007009949A (es) 2005-02-16 2007-09-26 Schering Corp Pirazinil-piperazin-piperidinas sustituidas con heteroarilo con actividad antagonista de cxcr3.
AU2006214477A1 (en) 2005-02-16 2006-08-24 Pharmacopeia, Inc. Heterocyclic substituted piperazines with CXCR3 antagonist activity
AU2006214378A1 (en) 2005-02-16 2006-08-24 Pharmacopeia, Inc. Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
EP1853583B1 (en) 2005-02-16 2011-09-07 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
EP1853587B1 (en) 2005-02-16 2011-08-03 Schering Corporation Novel heterocyclic substituted pyridine or phenyl compounds with cxcr3 antagonist activity
MX2007009947A (es) 2005-02-16 2007-09-26 Schering Corp Piperazin-piperidinas sustituidas con pirazinilo con actividad antagonista de cxcr3.
WO2006088836A2 (en) 2005-02-16 2006-08-24 Schering Corporation Piperazine-piperidines with cxcr3 antagonist activity
WO2007002293A2 (en) 2005-06-22 2007-01-04 Chemocentryx, Inc. Azaindazole compounds and methods of use
US7777035B2 (en) 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
US20080312215A1 (en) 2005-06-28 2008-12-18 Pharmacopeia Drug Discovery, Inc. Substituted [1,4]-diazepanes as CXCR3 antagonists and their use in the treatment of inflammatory disorders
US7754724B2 (en) 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
TW200738701A (en) 2005-07-26 2007-10-16 Du Pont Fungicidal carboxamides
JP2009511582A (ja) 2005-10-11 2009-03-19 シェーリング コーポレイション Ｃｘｃｒ３拮抗薬活性を有する置換複素環式化合物
NZ595182A (en) 2005-10-18 2012-12-21 Janssen Pharmaceutica Nv Pharmaceutical uses of 4-cyano-1H-imidazole-2-carboxylic acid { 2-cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl} -amide
US20090143413A1 (en) * 2005-11-29 2009-06-04 Adams Alan D Thiazole Derivatives as CXCR3 Receptor Modulators
EP1962605A2 (en) * 2005-12-12 2008-09-03 Merck & Co., Inc. 2-arylthiazole derivatives as cxcr3 receptor modulators
WO2007076318A2 (en) 2005-12-21 2007-07-05 Smithkline Beecham Corporation Camphor-derived cxcr3 antagonists
WO2007100610A2 (en) 2006-02-23 2007-09-07 Merck & Co., Inc. Pyridine, pyrimidine and pyrazine derivatives as cxcr3 receptor modulators
EP1996577B1 (en) 2006-03-21 2016-02-10 Merck Sharp & Dohme Corp. Heterocyclic substituted pyridine compounds with cxcr3 antagonist activity
SG171592A1 (en) 2006-04-20 2011-06-29 Janssen Pharmaceutica Nv Method of inhibiting c-kit kinase
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
FR2903405B1 (fr) 2006-07-04 2011-09-09 Pasteur Institut Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications
MX2009000577A (es) 2006-07-14 2009-03-09 Schering Corp Compuestos de piperazina sustituida heterociclica con actividad antagonista de cxcr3.
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
WO2008079279A1 (en) 2006-12-22 2008-07-03 Schering Corporation Heterocyclic compounds with cxcr3 antagonist activity
WO2008091594A2 (en) 2007-01-24 2008-07-31 E. I. Du Pont De Nemours And Company Fungicidal mixtures
CN101622245B (zh) 2007-01-25 2014-09-10 纳幕尔杜邦公司 杀真菌酰胺
WO2009020534A2 (en) 2007-08-03 2009-02-12 Schering Corporation Method of treating cxcr3 mediated diseases using heterocyclic substituted piperazines
TWI428091B (zh) 2007-10-23 2014-03-01 Du Pont 殺真菌劑混合物
US20110124867A1 (en) 2007-12-18 2011-05-26 Schering Corporation Process and intermediates for the Synthesis of heterocyclic Substituted Piperazines with CXCR3 Antagonist Activity
US8349870B2 (en) 2008-01-25 2013-01-08 E I Du Pont De Nemours And Company Fungicidal hetercyclic compounds
AU2009206522B2 (en) 2008-01-25 2013-12-19 E. I. Du Pont De Nemours And Company Fungicidal amides
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
BRPI0910837B1 (pt) 2008-04-30 2017-03-07 Bayer Cropscience Ag ésteres e tioésteres tiazol-4-carboxílicos, seus usos, e método e composição para controlar fungos fitopatogênicos prejudiciais
EP2166006A1 (en) * 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
CN102216296B (zh) 2008-10-01 2015-03-18 拜耳作物科学公司 作为作物保护剂的杂环取代的噻唑类
KR101052065B1 (ko) 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
CN102227423B (zh) 2008-12-02 2015-06-17 纳幕尔杜邦公司 杀真菌杂环化合物
MX2011006042A (es) 2008-12-11 2011-07-04 Bayer Cropscience Ag Tiazoliloximeteres y tiazolilhidrazonas como agentes fitosanitarios.
EP2424840B1 (en) * 2009-04-27 2014-08-06 Boehringer Ingelheim International GmbH Cxcr3 receptor antagonists
US8362249B2 (en) 2009-04-27 2013-01-29 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
EP2272846A1 (de) 2009-06-23 2011-01-12 Bayer CropScience AG Thiazolylpiperidin Derivate als Fungizide
UA107938C2 (en) 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
WO2011018401A1 (en) 2009-08-12 2011-02-17 Syngenta Participations Ag Microbiocidal heterocycles
WO2011051243A1 (en) 2009-10-29 2011-05-05 Bayer Cropscience Ag Active compound combinations
KR20120101019A (ko) 2009-10-30 2012-09-12 바이엘 크롭사이언스 아게 헤테로아릴피페리딘 및 -피페라진 유도체
JP5785560B2 (ja) 2009-12-21 2015-09-30 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 殺真菌剤としてのビス（ジフルオロメチル）ピラゾール
US8952004B2 (en) 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
MX2012012460A (es) 2010-04-28 2012-11-21 Bayer Cropscience Ag Derivados de cetoheteroarilpiperidina y de cetoheteroarilpiperazin a como fungicidas.
US8815775B2 (en) 2010-05-18 2014-08-26 Bayer Cropscience Ag Bis(difluoromethyl)pyrazoles as fungicides
US8722678B2 (en) 2010-05-20 2014-05-13 E I Du Pont De Nemours And Company Fungicidal oximes and hydrazones
CN103025723A (zh) 2010-05-27 2013-04-03 拜尔农作物科学股份公司 作为杀真菌剂的吡啶基羧酸衍生物
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
US8759527B2 (en) 2010-08-25 2014-06-24 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
PE20141002A1 (es) 2010-10-27 2014-08-17 Bayer Ip Gmbh Derivados de heteroarilpiperidina y -piperazina como fungicidas
WO2012069633A1 (en) 2010-11-25 2012-05-31 Syngenta Participations Ag Microbicidal heterocycles
AU2011344161A1 (en) 2010-12-17 2013-06-20 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
WO2012104273A1 (de) 2011-02-01 2012-08-09 Bayer Cropscience Ag Heteroarylpiperidin und -piperazinderivate als fungizide
WO2012107477A1 (en) 2011-02-10 2012-08-16 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2012107475A1 (en) 2011-02-10 2012-08-16 Syngenta Participations Ag Microbiocidal pyrazole derivatives
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
EP2755971B1 (de) 2011-09-15 2017-12-20 Bayer Intellectual Property GmbH Piperidinpyrazole als fungizide
WO2013056915A1 (en) 2011-10-18 2013-04-25 Syngenta Participations Ag Microbiocidal pyrazole derivatives
BR112014009086A2 (pt) 2011-10-18 2017-05-09 Syngenta Participations Ag derivados pirazol microbicidas
US8642774B2 (en) 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
WO2013110134A1 (en) 2012-01-25 2013-08-01 Spinifex Pharmaceuticals Pty Ltd Heterocyclic compounds and methods for their use
BR112014018714A8 (pt) 2012-02-02 2017-12-26 Actelion Pharmaceuticals Ltd Compostos de 4-(benzoimidazol-2-il)-tiazol e derivados de aza relacionados
WO2013127784A1 (en) 2012-03-02 2013-09-06 Syngenta Participations Ag Microbiocidal pyrazole derivatives
IN2012DE00621A (es) 2012-03-02 2015-07-17 Syngenta Participations Ag
AU2013273222B2 (en) 2012-06-04 2017-11-02 Idorsia Pharmaceuticals Ltd Benzimidazole-proline derivatives
WO2014062938A1 (en) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Rory modulators
WO2014075873A1 (en) 2012-11-13 2014-05-22 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2014075874A1 (en) 2012-11-13 2014-05-22 Syngenta Participations Ag Microbiocidal pyrazole derivatives
CA2894492A1 (en) 2012-12-11 2014-06-19 Takeda Pharmaceuticals Company Limited Heterocyclic compound
JP6430494B2 (ja) 2013-06-24 2018-11-28 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 殺真菌剤としてのピペリジンカルボン酸誘導体
EP3035800B1 (en) 2013-08-22 2019-10-09 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
AR102256A1 (es) 2014-10-15 2017-02-15 Actelion Pharmaceuticals Ltd Derivados biaromáticos básicos antibacterianos con sustitución de aminoalcoxi
EP3245203B1 (en) 2015-01-15 2018-11-14 Idorsia Pharmaceuticals Ltd Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015011099A1 (en) 2013-07-22 2015-01-29 Actelion Pharmaceuticals Ltd 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives

Also Published As

Publication number Publication date
RU2017128880A (ru) 2019-02-15
KR20170102355A (ko) 2017-09-08
CN107207491B (zh) 2020-08-25
WO2016113346A1 (en) 2016-07-21
PL3256469T3 (pl) 2019-05-31
EP3256469B1 (en) 2018-11-28
TWI698434B (zh) 2020-07-11
CA2972954A1 (en) 2016-07-21
MX2017009292A (es) 2018-02-09
BR112017015116A2 (pt) 2018-04-10
EP3256469A1 (en) 2017-12-20
ES2712727T3 (es) 2019-05-14
CA2972954C (en) 2023-08-29
JP6595003B2 (ja) 2019-10-23
JP2018502162A (ja) 2018-01-25
US10047080B2 (en) 2018-08-14
TR201901977T4 (tr) 2019-03-21
RU2017128880A3 (es) 2019-06-06
AR103399A1 (es) 2017-05-10
RU2706232C2 (ru) 2019-11-15
AU2016207990B2 (en) 2020-01-30
CN107207491A (zh) 2017-09-26
US20180009800A1 (en) 2018-01-11
AU2016207990A1 (en) 2017-08-31
TW201632518A (zh) 2016-09-16

Similar Documents

Publication Publication Date Title
KR102568469B1 (ko) Cxcr3 수용체 조정제로서의 (r)-2-메틸-피페라진 유도체
EP3245203B1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
KR102295416B1 (ko) 1-(피페라진-1-일)-2-([1,2,4]트리아졸-1-일)-에타논 유도체
WO2018011265A1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant